Purpose: Multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer (BC) has not been documented. Although radical cystectomy (RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatment option. In the absence of randomized studies, this study compared the oncologic outcomes between patients treated with RC or TMT by using a propensity score matched-cohort analysis. Methods: Data from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were reviewed retrospectively. Those who received TMT for MIBC were identified and matched (for sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treatment date, age, carcinoma in situ status, and hydronephrosis) with propensity scores to patients who underwent RC. Overall survival and diseasespecific survival (DSS) were assessed with Cox proportional hazards modeling and a competing risk analysis, respectively. Results: A total of 112 patients with MIBC were included after matching (56 who had been treated with TMT, and 56 who underwent RC). The median age was 68.0 years, and 29.5% had stage cT3/cT4 disease. At a median followup of 4.51 years, there were 20 deaths (35.7%) in the RC group (13 as a result of BC) and 22 deaths (39.3%) in the TMT group (13 as a result of BC). The 5-year DSS rate was 73.2% and 76.6% in the RC and TMT groups, respectively (P = .49). Salvage cystectomy was performed in 6 (10.7%) of 56 patients who received TMT. Conclusion: In the setting of a MDBCC, TMT yielded survival outcomes similar to those of matched patients who underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to discuss various treatment options, including organ-sparing TMT.
options are available to patients regardless of the stage at presentation.
The traditional treatment of muscle-invasive bladder cancer (MIBC) has been radical cystectomy (RC). Bladder-sparing strategies have emerged as a valid treatment option during the past decades. Recent data from many noncomparative single-arm series and Radiation Therapy Oncology Group protocols demonstrated that selected patients with MIBC experience excellent outcomes and experience preservation of a functioning bladder with trimodal therapy (TMT), which consists of debulking transurethral resection of bladder tumor (TURBT), chemotherapy for radiation sensitization, and external beam radiotherapy. [10] [11] [12] [13] To date, only one small, nonadjusted, case-control series of TMT versus RC in MIBC has been reported, which demonstrated no difference between groups. 14 A propensity score adjusted direct comparison of TMT to RC in MIBC has not been reported.
Radiotherapy alone, radiotherapy and concurrent cisplatin chemotherapy, or neoadjuvant chemotherapy (NAC) followed by radiotherapy have been performed for more than three decades at the Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Canada. 11 The increasing complexity of treatment decisions and the need to offer various treatment options, including RC and TMT, for eligible patients with MIBC were recognized, and a weekly multidisciplinary bladder cancer clinic (MDBCC) was established at the center in 2008. This study aimed to assess changes in care plans after multidisciplinary assessment and to compare oncologic outcomes between patients with MIBC who were treated with RC or TMT in the MDBCC by using a propensity score analysis.
■ Methods

■ MDBCC overview
The MDBCC was initiated as a weekly, referral-based outpatient clinic held in the cystoscopy suite of UHN, where patients with complex BC cases were referred for evaluation and second opinion by a multidisciplinary team that specialized in BC. Administrative coordinators prepared a summary of patient data, which included pathology review and imaging, before the patients' clinic visits. Clinical information was summarized in the bladder informatics tool (eCancerCareBladder), as reported previously. 15 In the MDBCC, all patients were evaluated by a multidisciplinary team composed of one of four urologic oncologists (G.S.K., N.E.F., M.A.S.J., A.R.Z.) and one of four radiation oncologists (P.C., R.G.B., M.M., P.W.), all of whom have expertise in BC care. 16 A BC expert medical oncologist (S.S.S.) was available for immediate, same-day consultation. Pathology review by expert genitourinary (GU) pathologists was initiated in case of initial assessment by a non-GU pathologist, variant histology, or doubt of the TURBT stage. Patient assessment involved a thorough history and physical examination, detailed review of external reports and available imaging, and cystoscopic evaluation with surgical and radiation oncologists in attendance. After multidisciplinary discussion, consensus recommendations for additional investigations (eg, pathology review by uropathology, additional imaging, and/or transurethral reresections) or definitive treatment were made.
■ MDBCC patients
All consecutive patients with BC referred to the MDBCC between April 2008 and December 2012 were identified retrospectively and included in the study to assess the impact of additional investigations and treatment decision in the clinic, and patients were identified and included up to December 2013 for the propensity score analysis. Baseline parameters of patients were recorded from electronic hospital charts. Electronically archived referral letters were used to identify the initial proposed treatment plan. Post-MDBCC disease stage and definitive treatment were recorded. Posttreatment outcome results were retrieved from electronic hospital charts. Institutional research ethics board approval was obtained (REB 10-0367-CE, 15-8727-CE).
■ Treatment
After clinic assessment and review of additional investigations and/or data (when necessary), final treatment decisions were presented to the patient with all physicians present. Patients with metastatic disease (regional and systemic) were referred for primary chemotherapy. Patients with localized non-muscle-invasive bladder cancer (NMIBC) were offered additional reresection, intravesical therapy, RC, radiotherapy, or enrollment in clinical trials. Patients with localized, nonmetastatic MIBC were assessed for their candidacy for TMT, RC, and/or clinical trials. RC consisted of cystoprostatectomy in men or anterior exenteration in women with bilateral pelvic lymph node dissection (template at the surgeon's discretion) and urinary diversion (ileal conduit, ileal neobladder, or Indiana pouch).
Patients with a history of pelvic radiotherapy who underwent RC were excluded from the propensity score analysis, because they would not be eligible for both treatment modalities. Candidates for TMT had (1) tumors < 5 cm, (2) solitary tumors, (3) minimal to no hydronephrosis, (4) good bladder function, and (5) no multifocal carcinoma in situ (CIS). Patients with limited CIS adjacent to the primary tumor and mild hydronephrosis, and patients at high risk for RC morbidity and mortality were not excluded from TMT consideration. If patients were candidates for TMT and RC, both were discussed, and the discussion included expected outcomes and complications.
The merits of perioperative chemotherapy using a shared decision-making process (NAC for patients who received TMT, NAC vs. adjuvant chemotherapy [AC] for patients who underwent RC) were discussed with patients. The criteria for cisplatin-based NAC were an Eastern Cooperative Oncology Group (ECOG) status < 2, creatinine clearance > 60 mL/min, no grade 2 or worse hearing loss or neuropathy, and adequate cardiac function (less than New York Heart Association class III heart failure). 17 In addition to NAC criteria, AC was only offered to patients who underwent RC and who had pathologic stage pT3/4 and/or N+. NAC and AC consisted of four cycles of gemcitabine plus cisplatin. A debulking TURBT to remove all visible tumor was performed before concomitant chemoradiotherapy. Radio-opaque contrast (0.5-1 mL Lipiodol [ethiodized oil, Guerbet LLC, Bloomington, IN]) was injected cystoscopically at the periphery of the tumor resection site for radiation treatment planning and to facilitate radiation delivery. Daily image-guided intensity-modulated radiotherapy was delivered to the bladder and pelvic nodes to a dose of 46 Gy in 23 fractions with a sequential tumor boost of 20 Gy in 10 fractions (total, 66 Gy). Radiosensitization with concurrent singleagent cisplatin chemotherapy (40 mg/m 2 ) was administered weekly during therapy.
■ Follow-up
All patients were observed by a standardized protocol of clinic visits (quarterly visits in year 1, biannual visits in years 2 and 3, and annual visits thereafter). Visits involved history, physical examination, blood work, and urinary cytology. Patients who received TMT or RC underwent axial imaging (computed tomography or magnetic resonance imaging) biannually to detect recurrent disease and complications. Patients who received TMT also underwent cystoscopy and salvage RC if they developed MIBC. Random bladder biopsy was not routine. Intravesical therapy and the management of NMIBC intravesical recurrence were based on established guidelines.
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■ Outcomes
The immediate impact of MDBCC on BC management was assessed by determining how often MDBCC assessment changed the initial tumor stage and/or treatment plan. Any change in clinical tumor stage and/or treatment plan that resulted from MDBCC assessment was recorded. Change in treatment was attributed to revised stage and/or expert opinion. Overall survival (OS) and disease-specific survival (DSS) for patients who received TMT were compared with those propensity-matched patients who underwent RC.
■ Statistical analyses
Short-term changes in stage and treatment plan were reported with descriptive statistics for continuous variables (means and medians) and categoric variables (percentages). To assess long-term outcomes, propensity score matching of patients treated with TMT to patients treated with RC at the UHN from 2008 to 2013 was performed. 22 
■ Discussion
No randomized trials have directly compared RC and bladder preservation approaches with TMT, so there is a lack of level-1 evidence to guide patient management. The recent United Kingdom phase III trial, Selective Bladder Preservation Against Radical Excision (SPARE), unfortunately failed to accrue patients and resulted in premature closure. 23 Most series of bladder preservation, with few exceptions, 12, 13 have included a limited number of cases per center, which compounds the lack of randomized data. 10, 24 To overcome the limitations of published noncomparative retrospective studies, this study used propensity score matching with patients who underwent contemporary RC to generate comparable groups using stringent criteria. The data showed that TMT provides midterm survival outcomes comparable to RC in selected BC cases. This analysis supports the concept that multidisciplinary consultation with experts in BC care leads to improvements in BC staging, which may optimize treatment recommendations. Indeed, the MDBCC assessment resulted in treatment changes for 33% of referred patients, but, in the absence of a true control group, better outcomes remain unproven. Incorrect clinical staging, especially understaging, has been identified as a serious problem in BC, and improvements in the staging process are needed to achieve more accuracy and improved care for patients with BC. 5, 25 MDC enables assessment by multiple disciplines, with subsequent provision of specialty-specific input, enhances the likelihood of delivering optimal curative therapy, 26 adds an additional layer of checks and balances in the decision-making process to minimize errors in judgment, and maximizes the probability of adopting treatment strategies that are based on the highest levels of evidence. 27 Data from oncologic literature in other cancer types 6, 8, 9 support improved survival outcomes in patients who receive care via multidisciplinary team approaches, and this may also be the case for patients with BC.
Despite the purported benefits of MDC in oncology, its uptake in BC has been slow and may be responsible for some degree of undertreatment of many patients with MIBC. For example, a recent observational study that used propensity score analysis to compare the effectiveness of AC versus observation post cystectomy in 5,653 patients with pathologic T3-4 and/or pathologic node-positive BC demonstrated that a mere 23% received AC. AC was associated with improved survival in patients with locally advanced BC (HR, 0.70; 95% CI, 0.64 to 0.76). 28 Similar underuse of NAC in patients with MIBC has been reported. 26, 27 Data from the SEER-Medicare database on MIBC treatment show that a disturbing 51% of patients did not receive any definitive therapy. 28 Many of these patients may have been eligible for some form of multimodal therapy, although they may have been ineligible for RC.
Critics of TMT point to its potential lack of efficacy compared with RC or the absence of long-term data. A pooled analysis of six historical Radiation Therapy Oncology Group single-arm studies demonstrated a similar 5-year DSS rate of 71% compared with modern MIBC cystectomy series. 10 However, cystectomy series are not limited to select patients with smaller, unifocal tumors without CIS or hydronephrosis in which 5-year DSS rates with surgery may be closer to 80%, 29, 30 so robust or definitive conclusions are limited. Furthermore, although contemporary TMT series involve more highly selected populations, historical RT series have included a large proportion of patients not suitable for RC because of age, comorbidities, and/or disease extent, which could explain lower-than-expected survival rates in these series; this difference further clouds potential comparisons.
In this study, the near identical 5-year DSS for RC and TMT are in keeping with modern MIBC outcomes reported in cystectomy series 31, 32 and demonstrate excellent and comparable results of modern TMT in selected patients with MIBC. The series had a 10.7% salvage cystectomy rate for high-risk NMIBC and MIBC recurrences after TMT. The lack of toxicity-related cystectomies supports the tolerability of the regimen. The success of TMT requires the expertise not only of radiation and medical oncologists to deliver treatment but also of urologic oncologists experienced in surveying postradiation bladders (in which differentiation between posttreatment radiation changes and tumor recurrence is not always straightforward) and who can safely perform salvage cystectomy.
Limitations of this study include its retrospective nature and the associated selection The DSS and OS rates were nearly identical between surgery and chemoradiation at 5 years (DSS, 73% vs. 77%, respectively), so it seems rather unlikely that expansion of the cohort size would dramatically modify these initial findings. Third, the median follow-up of 4.51 years may be considered limited, although, in patients with BC, pertinent clinical outcomes are often reached with this length of follow-up. Fourth, we had no quality-of-life data but have initiated the collection of these data. Fifth, this is a single institution study, and there is the possibility that different centers may experience different outcomes. Sixth, because the study lacked a true control arm of non-MDBCC care we cannot definitively prove that changes we implemented in care as a result of multidisciplinary consultation resulted in improved care. Change in stage was used as a surrogate for appropriate treatment delivery. Finally, the best method by which MDC should be provided cannot be determined from this report. In the MDBCC, assessment and consultation occur in parallel, with multiple specialists providing input simultaneously, although BC medical oncologists and expert GU pathologists were not physically present in the clinic at the same time. Lack of a full multidisciplinary complement in the same physical space did not affect their input. Specifically, we have increased use of NAC from 7.7% to 47.6% with MDBCC initiation, 27 and well over half of the patients undergo pathologic specimen review, which suggests that this limitation does not preclude MDC. In our clinic, cystoscopic assessment of patients treated with TMT by urologic and radiation oncologists present simultaneously enables joint decision making regarding the need for additional investigations and/or procedures. Whether this model provides improved outcomes compared with consultations done sequentially is unclear. Optimal outcomes, we believe, can be achieved through multidisciplinary collaboration by GU-trained oncology caregivers, regardless of how care is provided.
In conclusion, the advantage of MDC is the ability to review all treatment options with patients in an unbiased fashion. We observed a change in tumor staging in more than a third of patients after review in the MDBCC with subsequent modifications of the initial treatment plans. These results show that selected patients who undergo TMT experience outcomes similar to those who undergo RC. Patients eligible for TMT should be offered the opportunity to discuss all therapeutic alternatives before treatment is selected. Rather than pitting surgery against TMT, choice of the right therapeutic option for the right patient with BC in the setting of MDC should be encouraged. • The DSS and OS rates were nearly identical between surgery and chemoradiation at 5 years (DSS, 73% vs. 77%, respectively), so it seems rather unlikely that expansion of the cohort size would dramatically modify these initial findings.
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